onlyTrustedInfo.comonlyTrustedInfo.comonlyTrustedInfo.com
Notification
Font ResizerAa
  • News
  • Finance
  • Sports
  • Life
  • Entertainment
  • Tech
Reading: Regeneron Pharmaceuticals to buy 23andMe for $256M
Share
onlyTrustedInfo.comonlyTrustedInfo.com
Font ResizerAa
  • News
  • Finance
  • Sports
  • Life
  • Entertainment
  • Tech
Search
  • News
  • Finance
  • Sports
  • Life
  • Entertainment
  • Tech
  • Advertise
  • Advertise
© 2025 OnlyTrustedInfo.com . All Rights Reserved.
Finance

Regeneron Pharmaceuticals to buy 23andMe for $256M

Last updated: May 18, 2025 8:00 pm
Oliver James
Share
3 Min Read
Regeneron Pharmaceuticals to buy 23andMe for 6M
SHARE

Regeneron Pharmaceuticals on Monday announced plans to purchase genetic testing company 23andMe for $256 million.

The New York-based drugmaker is set to take over 23andMe after winning a bankruptcy auction for the ailing firm, Regeneron said.

Regeneron plans to “continue all consumer genome services uninterrupted,” the company noted in a statement.

MORE: Stocks slide after Moody’s downgrades US debt

“We believe we can help 23andMe deliver and build upon its mission to help people learn about their own DNA and how to improve their personal health, while furthering Regeneron’s efforts to improve the health and wellness of many,” Regeneron President George Yancopoulos said.

In March, 23andMe filed for Chapter 11 bankruptcy, saying it would enter a “court-supervised” sale process. At the same time, the company’s CEO, Anne Wojcicki, resigned from her role as chief executive.

The move followed a series of setbacks for the company, including a 2023 class-action settlement over a data breach and a mass resignation among its board of directors in 2024.

Founded in 2006, 23andMe helped pioneer consumer genetic testing but faced difficulty turning the service into a sustainable business.

The bankruptcy elicited fears about the security of genetic data belonging to the company’s roughly 15 million customers.

Regeneron on Monday vowed to maintain the data privacy protocol employed by 23andMe.

“Regeneron intends to ensure compliance with 23andMe’s consumer privacy policies and applicable laws with respect to the treatment of customer data,” the company said.

MORE: Trump wants Apple to make iPhones in the US. Will it ever happen?

The acquisition of 23andMe will not include Lemonaid Health, a telemedicine service that 23andMe purchased for about $400 million in 2021.

Regeneron pointed to its own genetic testing of some 3 million people over the course of various research studies, saying the information had helped facilitate pharmaceutical breakthroughs.

“We share 23andMe’s founding vision of the power of genetics and data and the health benefits to individuals and society in understanding the human genome,” Regeneron said. “We believe we are uniquely suited to be responsible and effective stewards of 23andMe’s future, and we look forward to welcoming their talented team.”

ABC News’ Mary Kekatos contributed to this report.

Regeneron Pharmaceuticals to buy 23andMe for $256M originally appeared on abcnews.go.com

You Might Also Like

Salesforce sinks after missing revenue consensus for Q4

401(k): What the Average Person in Their 30s Has Saved

Why JetBlue Stock Is Gaining Altitude Today

How To Use PGP For Enhanced Privacy And Powerful OPSEC

Despite DOGE’s best efforts, government spending has risen more than 6% over Trump’s first 100 days

Share This Article
Facebook X Copy Link Print
Share
Previous Article Why Carrie Underwood Slipped Back into Her Old “American Idol” Looks as Judge and More Season 23 Style Facts (Exclusive) Why Carrie Underwood Slipped Back into Her Old “American Idol” Looks as Judge and More Season 23 Style Facts (Exclusive)
Next Article Russian fighter jet protects ‘shadow fleet’ vessel in first such move by Moscow, officials say Russian fighter jet protects ‘shadow fleet’ vessel in first such move by Moscow, officials say

Latest News

Reports: Mikal Bridges agrees to 4-year, 0 million extension with Knicks
Reports: Mikal Bridges agrees to 4-year, $150 million extension with Knicks
Sports July 31, 2025
A winner either way: José Caballero traded from Rays to Yankees while teams were playing each other
A winner either way: José Caballero traded from Rays to Yankees while teams were playing each other
Sports July 31, 2025
Favorites emerge to land disgruntled Commanders WR Terry McLaurin
Favorites emerge to land disgruntled Commanders WR Terry McLaurin
Sports July 31, 2025
MLB trade deadline: Ranking the top 50 trades, from a multitude of relievers to Carlos Correa’s return to Houston
MLB trade deadline: Ranking the top 50 trades, from a multitude of relievers to Carlos Correa’s return to Houston
Sports July 31, 2025
//
  • About Us
  • Contact US
  • Privacy Policy
onlyTrustedInfo.comonlyTrustedInfo.com
© 2025 OnlyTrustedInfo.com . All Rights Reserved.